伯基特淋巴瘤亚型的全基因组图谱
该研究对101例代表伯基特淋巴瘤(BL)三种临床亚型的肿瘤进行全基因组测序,鉴定出72个驱动基因,并结合CRISPR筛选进行功能注释。研究发现几乎所有驱动基因均存在编码和非编码突变,IGLL5、BACH2、SIN3A和DNMT1的编码与非编码突变被揭示;EBV感染与更高突变负荷相关,地方性BL在BCL7A和BCL6突变更频繁,而DNMT1、SNTB2和CTCF遗传改变较少;ID3沉默突变是所有亚型的共同特征,其蛋白主要结合TCF3和TCF4,体内敲除ID3可增强MYC效应导致快速肿瘤发生。
要点
- 全基因组测序揭示BL的72个驱动基因,编码和非编码突变均常见。
- ID3沉默突变是三种BL亚型的共同特征,其蛋白主要结合TCF3和TCF4。
- 地方性BL与散发性和免疫缺陷相关BL的基因突变谱存在差异。
核心结论
- BL的驱动基因广泛存在编码和非编码突变,凸显全基因组测序在识别驱动事件中的重要性。
- ID3沉默突变是所有BL亚型的共同特征,其功能与TCF3/TCF4结合及增强MYC效应相关。
研究设计与样本
- 对101例代表BL三种临床亚型(散发性、地方性、免疫缺陷相关)的肿瘤进行全基因组测序。
- 结合BL细胞系的CRISPR筛选对致癌驱动基因进行功能注释。
主要发现
- 共鉴定出72个驱动基因,几乎所有驱动基因均存在编码和非编码突变。
- IGLL5、BACH2、SIN3A和DNMT1存在编码和非编码突变。
- EBV感染与更高突变负荷相关,1型EBV的突变负荷高于2型EBV。
- 地方性BL较散发性或免疫缺陷相关BL在BCL7A和BCL6突变更频繁,而DNMT1、SNTB2和CTCF遗传改变较少。
- 体外实验显示ID3蛋白主要结合TCF3和TCF4;体内敲除ID3可增强MYC效应,导致快速肿瘤发生并与人类疾病表型一致。
临床怎么用
- 全基因组测序有助于全面识别BL的编码和非编码驱动突变。
- ID3突变及TCF3/TCF4结合特征可能为BL的病理机制提供线索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Burkitt lymphoma (BL) is an aggressive, MYC-driven lymphoma comprising 3 distinct clinical subtypes: sporadic BLs that occur worldwide, endemic BLs that occur predominantly in sub-Saharan Africa, and immunodeficiency-associated BLs that occur primarily in the setting of HIV. In this study, we comprehensively delineated the genomic basis of BL through whole-genome sequencing (WGS) of 101 tumors representing all 3 subtypes of BL to identify 72 driver genes. These data were additionally informed by CRISPR screens in BL cell lines to functionally annotate the role of oncogenic drivers. Nearly every driver gene was found to have both coding and non-coding mutations, highlighting the importance of WGS for identifying driver events. Our data implicate coding and non-coding mutations in IGLL5, BACH2, SIN3A, and DNMT1. Epstein-Barr virus (EBV) infection was associated with higher mutation load, with type 1 EBV showing a higher mutational burden than type 2 EBV. Although sporadic and immunodeficiency-associated BLs had similar genetic profiles, endemic BLs manifested more frequent mutations in BCL7A and BCL6 and fewer genetic alterations in DNMT1, SNTB2, and CTCF. Silencing mutations in ID3 were a common feature of all 3 subtypes of BL. In vitro, mass spectrometry-based proteomics demonstrated that the ID3 protein binds primarily to TCF3 and TCF4. In vivo knockout of ID3 potentiated the effects of MYC, leading to rapid tumorigenesis and tumor phenotypes consistent with those observed in the human disease.
引用
- Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019. PMID: 31558468. doi:10.1182/blood.2019001880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。